NicOx: Challenging the Cox-2s?
Executive Summary
Recent concerns over the cardiovascular risk profile of Cox-2 inhibitors strengthen the case for pain compound AZD 3582, a new formulation of naproxen in Phase II trials at AstraZeneca. For the compound's originator, NicOx, forthcoming trial results will be critical in validating the firm's founding concept: grafting a nitric oxide molecule onto existing generic drugs.
You may also be interested in...
NicOx's Naproxcinod: Hitting the NSAID Sweet Spot?
NicOx plans to retain at least some rights to its late-stage osteoarthritis candidate. But can an R&D focused biotech do primary care?
Alfama
The founders of European start-ups Alfama and hemoCORM Ltd. are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.
hemoCORM Ltd.
The founders of European start-ups hemoCORM Ltd. and Alfama are hoping to harness potentially therapeutic effects of carbon monoxide (CO) through developing a range of CO releasing molecules that deliver the molecule into the body under certain conditions.